Remodulin and Revlimid drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Remodulin (treprostinil sodium) and Revlimid (lenalidomide). Common drug interactions include death among females and device failure among males.

The phase IV clinical study analyzes what interactions people have when they take Remodulin and Revlimid. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Remodulin?

Remodulin has active ingredients of treprostinil sodium. It is often used in primary pulmonary hypertension. eHealthMe is studying from 55,843 Remodulin users. Check the latest studies of Remodulin.

What is Revlimid?

Revlimid has active ingredients of lenalidomide. It is often used in multiple myeloma. eHealthMe is studying from 378,026 Revlimid users. Check the latest studies of Revlimid.

On Jul, 06, 2026

14 people who take Remodulin and Revlimid together, and have interactions are studied.

Remodulin and Revlimid drug interactions.

What are the common drug interactions of Remodulin and Revlimid, by gender? *:

female:

Death
Febrile neutropenia (fever with reduced white blood cells)
Gingivitis (inflammation of gums)
Gingivitis ulcerative (infection of gums with ulcers)
Pharyngitis (inflammation of the pharynx, causing a sore throat)
Renal failure (kidney dysfunction)
Sepsis (a severe blood infection that can lead to organ failure and death)
Urinary tract infection
Infusion site haemorrhage (bleeding from infusion site)
Injection site haemorrhage (bleeding from injection site)

male:

Device failure
Infusion site haemorrhage (bleeding from infusion site)
Pain in jaw
Sleep disorder
Vomiting
Infusion site erythema (reddening of the skin at infusion site)
Injection site erythema (redness at injection site)
Injection site induration
Injection site infection
Injection site pain

What are the common drug interactions of Remodulin and Revlimid, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Infusion site haemorrhage (bleeding from infusion site)
Injection site haemorrhage (bleeding from injection site)
Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)

40-49:

Injection site erythema (redness at injection site)
Injection site induration
Injection site infection
Injection site pain
Injection site swelling
Pruritus (severe itching of the skin)
Purulent discharge (discharge that contains pus)

50-59:

Anaemia (lack of blood)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Splenomegaly (enlargement of spleen)

60+:

Death
Febrile neutropenia (fever with reduced white blood cells)
Dysarthria (speech disorder)
Fall
Gait disturbance
Head injury
Pneumonia
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Eyelid disorder
Infusion site haemorrhage (bleeding from infusion site)

What are the existing conditions these people have? *

Pulmonary Hypertension (increase in blood pressure in the lung artery): 2 people, 14.29%
Urinary Tract Infection: 1 person, 7.14%
Hepatitis B: 1 person, 7.14%
Bone Pain: 1 person, 7.14%
Constipation: 1 person, 7.14%
Cor Pulmonale Chronic (long lasting enlargement of the right ventricle of the heart): 1 person, 7.14%
Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it): 1 person, 7.14%
Diabetes: 1 person, 7.14%
Diarrhea: 1 person, 7.14%
Fever: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Remodulin and Revlimid?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously